Table 1 Cohort description
From: SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults
Extended cohort | SARS-CoV-2 RT-PCR+ | Negative Controls | |||
|---|---|---|---|---|---|
% (n) | Children | Adults | p-value | Children | Adults |
Total samples | 257 | 122 | 12 | 48 | |
Total participants | 146 | 85 | |||
Age (mean ± SD, range) | 9.4 ± 4.8, 0.25-17 | 39.5 ± 15.2, 18–71 | <2.2 × 10−16 | 9.6 ± 4.51, 2–14 years | 35.1 ± 13.44, 19-60 years |
Female | 47.9% (70) | 50.6% (43) | 0.79 | 67% (8) | 50.0% (29) |
Asymptomatic | 43.2% (63) | 14.1% (12) | 4.67 × 10−6 | ||
Mild/Moderate | 56.8% (83) | 85.9% (73) | |||
Severe/Critical | 0% (0) | 0% (0) | |||
Sample time point information – days post symptom onset (n = , median (IQR), range) | |||||
All time points | n = 257 15 (7–60), 0–206 days | n = 122 34.5 (11.5–62.8), 2–180 days | 0.012 | ||
Acute time points | n = 128 7 (3–10), 0–14 days | n = 40 8 (4.8–11), 2–14 days | 0.18 | ||
Convalescent time points | n = 129 60 (36–97), 15-206 days | n = 82 53 (33.8–85), 15–180 days | 0.23 | ||
Participants with 1 timepoint | 43.8% (64) | 58.8% (50) | 0.0018 | ||
Participants with 2 timepoints | 38.4% (56) | 38.8% (33) | |||
Participants with 3 timepoints | 15.8% (23) | 2.4% (2) | |||
Participants with 4 timepoints | 2.1% (3) | 0 | |||
